---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-142232"
form_type: "8-K"
ticker: "DYN"
cik: "0001818794"
company_name: "Dyne Therapeutics, Inc."
filed_at: "2024-05-20T23:59:59+00:00"
generated_at: "2026-06-01T13:11:06.587185+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Dyne: DYNE-101 achieves 27% splicing correction at 3 months; DYNE-251 shows 3.22% dystrophin expression in DMD

## Summary
- DYNE-101 5.4 mg/kg Q8W showed 27% mean splicing correction across 22-gene panel at 3 months, all participants responded.
- DYNE-101 improved myotonia (vHOT) by 4.5 sec at 3 months (5.4 mg/kg) and 4.4 sec at 12 months (1.8 mg/kg Q4W).
- DYNE-251 10 mg/kg monthly achieved mean unadjusted dystrophin 3.22% (7.64% muscle-adjusted) vs 0.30% for weekly eteplirsen.
- DYNE-251 showed trends in functional endpoints: NSAA, SV95C, 10-Meter Walk/Run, and Time to Rise at 6 months.
- Favorable safety for both; FDA accelerated approval pathways confirmed; registration pathway update expected by end of 2024.

## SEC filing metadata
- accession: 0001193125-24-142232
- form_type: 8-K
- ticker: DYN
- cik: 0001818794
- company_name: Dyne Therapeutics, Inc.
- filed_at: 2024-05-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818794/000119312524142232/0001193125-24-142232-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818794/000119312524142232/d821973d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-142232
- JSON: https://secwatch.observer/filing/0001193125-24-142232.json
- Plain text: https://secwatch.observer/filing/0001193125-24-142232.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.